Advancing digital health: FDA innovation during COVID-19
Digital health products have played an important role in the COVID-19 response, from supporting the remote monitoring of patients to enabling continuity in data collection for clinical trials. The U.S. Food and Drug Administration (FDA) has issued a number of temporary policies to support digital he...
Enregistré dans:
Auteurs principaux: | Kushal Kadakia, Bakul Patel, Anand Shah |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e6cd3676b6b641c1a1a0670ff13db78c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database
par: Stan Benjamens, et autres
Publié: (2020) -
Challenges for the evaluation of digital health solutions—A call for innovative evidence generation approaches
par: Chaohui Guo, et autres
Publié: (2020) -
Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries
par: Sara Gerke, et autres
Publié: (2020) -
Evidence for the effectiveness of digital health
par: Joseph C. Kvedar
Publié: (2020) -
Applications of digital health for public health responses to COVID-19: a systematic scoping review of artificial intelligence, telehealth and related technologies
par: Dinesh Visva Gunasekeran, et autres
Publié: (2021)